Darabi, H; Bolla, MK; Shu, XOu; Cox, A; Cross, SS; Luben, R; Khaw, K; Choi, JiY; Kang, D; Hartman, M; Lim, W; Kabisch, M; Dennis, Joe; Torres, D; Jakubowska, A; Lubinski, Jan; Mckay, J; Sangrajrang, S; Toland, AE; Yannoukakos, D; Shen, CY; Yu, J; Ziogas, A; Wang, Qin; Schoemaker, MJ; Swerdlow, A; Borresen-Dale, AL; Kristensen, V; French, JD; Edwards, SL; Dunning, AM; Easton, DF; Hal, Per; Chenevix-Trench, G; Canisius, S; Scott, CG; Apicella, C; Hopper, JL; Southey, MC; Stone, J; Broeks, A; Mccue, K; Schmidt, MK; Scott, RJ; Lophatananon, A; Muir, K; Beckmann, MW; Ekici, AB; Fasching, PA; Heusinger, K; Dos-Santos-Silva, I; Peto, J; Beesley, J; Tomlinson, Ian; Sawyer, EJ; Burwinkel, B; Marme, F; Guenel, P; Truong, T; Bojesen, SE; Flyger, H; Benitez, J; Gonzalez-Neira, A; Michailidou, K; Anton-Culver, H; Neuhausen, SL; Arndt, V; Brenner, H; Engel, C; Meindl, A; Schmutzler, RK; Arnold, N; Brauch, H; Hamann, Ute; Kareti, S; Subash, P; Nevanlinna, HH
Alzheimer's disease (AD) can be treated by the inhibition of Beta Amyloid protein (Ab) and inhibition of Acetylcholinesterase (ACHE). Anti-Alzheimer's potential phytoconstituents from Neolamarckia cadamba methanolic bark extracts were identified through GC-MS/MS analysis and in silico molecular docking analysis. Powdered bark sample was subjected to extract by soxhlet extractor with n-hexane, chloroform and methanol solvents respectively. The methanolic extract was taken for GC-MS/MS analysis, the observed chromatogram was revealed the presence of 61 constituents in the methanolic extract, 59 new phytoconstituents were identified which were not reported earlier as constituents any part of N. cadamba. GC-MS/MS detected phytoconstituents were analysed through the docking analysis by iGEMDOCK software against A beta (PDB ID: 2LMN) and ACHE (PDB ID: 3LII) and compared with standard known inhibitors of galantamine and curcumin. Docking analysis binding energy was determined and verified by Discovery studio visulaizer. Both inhibition assay top 5 best dock energy compounds were analysed through the in silico modeling through admetSAR web portal for parameters of intestinal absorption, blood brain barrier permeation, carcinogencity, and acute oral toxicity were determined. From that heptadecanoic acid, 16-methyl-, methyl ester; beta-sitosterol acetate and octadecanoic acid, 2-hydroxy-, methyl ester inhibitors were identified. Further the top lead successful compound of each target molecular interactions were detected by LigPlot analysis. From this research these three compounds are best to treat AD than standard. Isolation of individual compounds would, however, help to find new compounds for other diseases and lead molecules for AD were identified. (C) 2020 Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).